Objective. ABCG2 rs2231142 (Q141K) has been reported to be associated with poor response to allopurinol, while there are conflicting data on the association between the genetically independent ABCG2 rs10011796 variant and allopurinol response. The aim of this study was to replicate the association of ABCG2 rs2231142 and rs10011796 with allopurinol response and perform a meta-analysis.
Introduction
The central strategy for gout management is long-term urate-lowering therapy (ULT). International guidelines endorse a serum urate (SU) of <6 mg/dl in patients receiving ULT [1, 2] . Allopurinol is the recommended first-line ULT for most patients with gout [1, 2] . Allopurinol dosing remains controversial, particularly in chronic kidney disease, due to concerns about the risk of allopurinol hypersensitivity syndrome [2] . This is reflected by differences in allopurinol dosing recommendations from EULAR [2] and ACR [1] . Adjusting allopurinol dose according to kidney function is one of the key reasons for therapeutic failure, along with poor adherence. The ability to predict response or lack of response to allopurinol would help guide therapeutic decision making, particularly where clinicians may not wish to use allopurinol at doses above those based on kidney function.
Most pharmacogenetic studies have focused on predicting allopurinol-related severe cutaneous adverse reactions, with HLA-B*5801 identified as a key risk allele. In 2015, results of a genome-wide association study of allopurinol response reported that two genetically independent single nucleotide polymorphisms (SNPs) in ABCG2, rs2231142 and rs10011796, were associated with poor response to allopurinol [3] . The definition of response was a change in SU and there was no assessment of adherence. Using a strict definition of poor response according to SU (56 mg/dl despite allopurinol >300 mg/day) and with confirmed adherence (plasma oxypurinol >20 mmol/l), we previously replicated the association of Wen et al. [3] between poor response and ABCG2 rs2231142 but not rs10011796 in a New Zealand gout cohort [4] .
Both rs2231142 and rs10011796 independently associate with SU [5, 6] . rs2231142 encodes the Q141K non-synonymous variation in ABCG2, whereby the 141 K variant causes $50% reduced efflux of uric acid [7] . The association of rs10011796 with SU is independent of rs2231142 and is likely mediated through control of expression and/or transcript processing of ABCG2 [6] . The molecular mechanism whereby either of these variants could influence allopurinol response is not obvious. Given that the effects of rs2231142 and rs10011796 are genetically independent it is reasonable to hypothesize that rs10011796 may have an independent effect on allopurinol response.
The aim of this study was to replicate the association of rs10011796 with allopurinol response and to further replicate the association of rs2231142 with allopurinol response [3] .
Methods
Patients were drawn from two separate gout cohorts. The first cohort (n = 395) comprised a subset of participants in the Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO) [8] , where allopurinol dose, SU and a plasma sample were available for a single visit. In this study, the investigators were encouraged but not required to increase allopurinol dose to achieve target urate, with 61.9% of the subset included in this analysis having had at least one increase in allopurinol dose. The second cohort (n = 296) comprised a subset of participants from the Genetics of Gout in Aotearoa New Zealand (NZ) study where allopurinol dose, plasma oxypurinol and SU were available for a single visit. A subgroup (264/296) participated in our previous rs2231142 allopurinol response study; the extra participants could be classified as responder or nonresponder after allopurinol dose escalation [4] . All participants in both cohorts fulfilled the ARA preliminary classification criteria for gout [9] . All participants provided written informed consent and ethical approval was obtained from The New Zealand Multiregional Ethics Committee (MEC05/10/130) and in the United States Schulman Central Institutional Review Board (IRB) (201102890).
Participants were classified based on response to allopurinol. Good responders were defined as SU <6 mg/dl on allopurinol 4300 mg/day and poor responders as SU 56 mg/dl despite allopurinol >300 mg/day.
Measurement of plasma oxypurinol
High-performance liquid chromatography was used to measure plasma oxypurinol. Participants were considered to be adherent with allopurinol if plasma oxypurinol was >20 mmol/l.
Genotyping
Peripheral blood was collected (35 ml) and genomic DNA extracted using guanidine isothiocyanate. Genotyping was performed using the pre-designed SNP TaqMan assays for ABCG2 SNPs rs2231142 and rs10011796 (assay IDs: C_15854163 and C_9510320_10) from Applied Biosystems (Carlsbad, CA, USA) using a Lightcycler 480 Real-Time PCR (RT-PCR) System (Roche Applied Science, Indianapolis, IN, USA). To generate principal components the Illumina Infinium CoreExome v24 bead chip platform was used to genotype 505 of the participants. Bead chip genotypes were autoclustered using GenomeStudio v2011.1 software (Illumina, San Diego, CA, USA). The Illumina GenomeStudio best practice guidelines and quality control protocols of Guo et al. [10] were applied to these auto-clustered genotypes [11] . Whole-genome principal component analysis vectors were calculated using SmartPCA (EIGENSOFT v6.0.1), with an output of 10 eigenvectors, no outlier removal and no population size limit.
Statistical analysis
Statistical analysis was undertaken using R statistical software package v3.3.1. Logistic and linear regression (as appropriate) was used to test for association between clinically relevant variables in both cohorts; age, sex, BMI, ethnicity, estimated glomerular filtration rate (eGFR), diuretic use, alcohol consumption and presence of tophus with poor response as outcome (Table 1 ). There were insufficient data for SU prior to ULT (baseline SU) (36% for the LASSO cohort and 85% for the NZ cohort) to be included in association analyses of genotype against allopurinol response. However, we have previously shown that adjustment for baseline SU did not influence association of rs2231142 with allopurinol response [4] .
A P-value <0.05 was considered statistically significant. Association of ABCG2 SNPs rs2231142 and rs10011796 with poor response was tested with logistic regression with adjustments made for age, sex, BMI, ethnicity and eGFR. We had 100% power to detect the association of rs2231142 with allopurinol response previously described by Roberts et al. [4] in the LASSO cohort and 63% power to detect the association of rs10011796 effect size previously described [3] in the LASSO and NZ combined cohort. Results were combined by meta-analysis using the Meta package in R. An adjusted linear regression was performed on each cohort to test for association between poor response and BMI. An interaction term was included in the regression analyses to test for interaction between variables. This analysis was additionally stratified by sex. Results were meta-analysed and the P difference between the male and female meta-analysis was calculated.
Results
Of the LASSO cohort 24.3% (96/395) and of the NZ cohort 13.5% (40/296) either did not fit the pre-defined response criteria and/or had plasma oxypurinol suggestive of nonadherence and were excluded. Of the LASSO cohort 46.5% (139/299) and of the NZ cohort 50.8% (130/256) were defined as poor responders. Demographics of both cohorts are shown in Table S1 , available as supplementary data at Rheumatology online.
Each covariate was tested individually in a logistic regression analysis of allopurinol response. There was strong evidence in both cohorts for association of increased age, increased BMI and non-Caucasian ethnicity with reduced allopurinol response, and evidence in the NZ cohort for association of increased eGFR and male sex with reduced response (Table S1 , available as supplementary data at Rheumatology online). All five variables were included in subsequent logistic regression models of genotype against allopurinol response.
There was evidence for association of both variants with allopurinol response in the LASSO cohort in a model that did not include adjustment for genotype of the other SNP [rs2231142, odds ratio (OR) = 2.56, P = 7.65 Â 10 À5 and rs10011796, OR = 1.55, P = 0.017]. Adjusting by rs2231142 genotype resulted in no evidence for association of rs10011796 (OR = 1.21, P = 0.33) ( Table 1 ). There was evidence for association of rs2231142 (T-allele associated with poor response) but not rs10011796 with allopurinol response in the NZ cohort in the fully adjusted model (Table 1 ; OR = 2.51, P = 2.4 Â 10 À4 and OR = 0.88, P = 0.60, respectively). Meta-analysis of the cohorts provided evidence for association of rs2231142 (OR = 2.42, P = 6.7 Â 10 À7 ), but not of rs10011796 with allopurinol response (OR = 1.06, P = 0.69) (Fig. 1) . A pooled analysis incorporating into the logistic regression model the first four principal components (instead of ethnicity) derived from genome-wide genotype data that were available for 505 of the NZ and LASSO participants also revealed strong evidence for association of rs2231142 [OR (95% CI) = 2.42 (1.67, 3.55), P = 3.9 Â 10
À6
] but not rs10011796 [OR = 1.11 (0.82, 1.51), P = 0.49] with poor response.
We investigated the relationship between BMI and allopurinol response, including stratification by sex (Table S2 , available as supplementary data at Rheumatology online). This revealed an association between BMI and response in the overall sample set ( = 4.36, S.E. = 0.69, P = 3.2 Â 10 À10 ) and a notable association of BMI on response in women in both cohorts ( = 13.59, S.E. = 3.75, P = 0.011 in LASSO and = 16.13, S.E. = 4.37, P = 1.2 Â 10 À3 in NZ). The value represents the change in BMI comparing poor with good allopurinol response, with an increase in BMI associated with poor response. There was no evidence for interaction between BMI and sex in determining allopurinol response [OR = 1.01 (1.00, 1.03), P = 0.15] in the combined (NZ and LASSO) dataset, after adjusting for rs2231142, age, ethnic class and eGFR.
We stratified the association analysis of genotype with allopurinol response as outcome. There was no evidence for an interaction between genotype and BMI in determining allopurinol response-the interaction terms for both rs2231142 and rs10011796 were not significant [OR = 0.85 (0.33, 2.12), P = 0.73 and OR = 0.73 (0.18, 2.47), P = 0.63, respectively, after adjusting for BMI, age, sex ethnic class and eGFR].
Finally, we combined rs2231142 and rs10011796 genotypes to create four groups and tested for association with allopurinol response (Table S3 , available as supplementary data at Rheumatology online). The strongest effect on response was seen in the rs2231142 T + and rs10011796 TÀ group (OR = 4.43, P = 0.022). There was no evidence for interaction between genotypes in determining allopurinol response [OR = 0.54 (0.13, 2.02), P = 0.37, after adjusting for BMI, age, sex ethnic class and eGFR].
Discussion
In a well phenotyped cohort of patients with gout from the LASSO study we have replicated the association between poor response to allopurinol and ABCG2 rs2231142, with meta-analysis providing strong evidence for the association (OR = 2.43, P = 6.2 Â 10 À7 ). We were unable to replicate the previously described association of rs10011796 with allopurinol response [3] . If there is an association, it is likely to be weak and the current study was inadequately powered to identify weak effects, with only 63% power to detect an association.
The mechanism by which ABCG2 alters allopurinol response remains unclear. The theory that the ABCG2 141 K variant might increase allopurinol and oxypurinol concentrations in renal tubular cells and decrease concentration in the tubule fluid, thereby reducing the inhibition of uric acid influx pumps within the kidney and hence allopurinol response, remains unproven [3] .
There are complex interactions between ABCG2 141 K, BMI, sex and urate. Genome-wide association studies have identified ABCG2 and SLC2A9 as having a strong influence on SU. ABCG2 has a weaker effect than SLC2A9, with each copy of the ABCG2 141 K allele associated with a 0.22 mg/dl increase in SU in Europeans [5] and a 0.14 mg/dl increase in East Asians [12] . There also appear to be sex-specific effects, with SLC2A9 having stronger effect in females and ABCG2 a stronger effect in males [13] . ABCG2 expression is up-regulated by oestrogen [14] . Elevated BMI is an important risk factor for hyperuricaemia and gout. BMI modulates the influence of genetic factors on SU; research into groups with the 141 K variant showed higher urate levels observed in lean people (BMI <25 kg/m 2 ) compared with those who are overweight or obese (BMI 525 kg/m 2 ) [15] . This effect of BMI was stronger in men than in women [15] . An important observation in our study is the association between BMI and allopurinol response, with a higher BMI associated with poor response, particularly in women. While it is possible that obesity impacts the pharmacokinetics of allopurinol, how such an effect could be stronger in women is unclear.
Interactions between BMI, sex and obesity in determining SU suggests that the association between rs2231142 and poor response to allopurinol may be related to pre-ULT urate levels, an important determinant of allopurinol P value adjusted by age, sex, BMI, ethnicity, eGFR and rs10011796 or rs2231142 respectively. PHet: P-value from the heterogeneity test within the meta-analysis. dose required to achieve target urate [16] ; we have previously reported that urate does not influence the association between ABCG2 rs2231142 and allopurinol response [4] . In addition, the sex affect appears unrelated to ABCG2 as there was no interaction between ABCG2 and sex observed in the current study.
Screening for ABCG2 141 K and using alternative ULT in those with the risk allele for poor response to allopurinol is unlikely to be cost effective given the current cost of genetic testing and the expense of alternate agents. As genetic testing becomes less expensive and more rapid, and cheaper generic versions of ULTs such as febuxostat become available, this may change. Intestinal ABCG2 has recently been shown to be inhibited by febuxostat in in vitro and murine models [17] . Whether ABCG2 SNPs are associated with febuxostat response is unknown.
The study has some limitations. There were insufficient data for SU prior to ULT (baseline SU) (36% for the LASSO cohort and 85% for the NZ cohort) to be included in the analysis; baseline SU is an important determinant and can help predict allopurinol dose required to achieve SU <6 mg/dl [16, 18] . However, we have previously shown in the NZ cohort that adjustment for baseline SU did not influence association of rs2231142 with allopurinol response [4] . In addition, not all participants in the LASSO subset had been through a treat-to-target SU protocol.
In conclusion, we replicated the association between ABCG2 141 K and poor response to allopurinol. Further research is required to determine the mechanism by which ABCG2 Q141K alters response to allopurinol.
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